Priority Review status expected to accelerate review period; PDUFA date set for December 19, 2018 If approved, brexanolone IV would be the first and only medication indicated for the treatment of postpartum depression CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sage Therapeutics (NASDAQ:
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at Bernstein’s 34 th Annual
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that members of the Sage management team will participate in a
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2018 , the Compensation Committee of Sage’s Board
New Drug Application for intravenous (IV) formulation of brexanolone as a treatment for postpartum depression submitted to U.S. Food and Drug Administration Significant progress achieved in launch readiness preparations in anticipation of potential 1H 2019 brexanolone IV launch Broad pipeline of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
Brexanolone IV submission is the Company’s first New Drug Application CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Sage Therapeutics (NASDAQ: SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 4, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 2, 2018 , the Compensation Committee of Sage’s
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at
